Nivolumab is an immune checkpoint inhibitor (ICI) and is used for the treatment of advanced nonsmall cell lung cancer (NSCLC). Several immune-mediated neurological adverse events associated with ICIs have been reported to date, such as Guillain-Barré syndrome. | Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immunerelated adverse events of nivolumab A case report